Allergan Plc (AGN) - Financial and Strategic SWOT Analysis Review

  • ID: 3678162
  • SWOT Analysis
  • 73 pages
  • GlobalData
  • Allergan plc
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Gilead Sciences Inc
  • MORE
Allergan Plc (AGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, women’s health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc Key Recent Developments

Feb 21, 2018: New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis
Feb 16, 2018: Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
Feb 06, 2018: Allergan Reports Total Net Revenue Of $4.33 Billion In The Fourth Quarter Of 2017
Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer
Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Gilead Sciences Inc
  • MORE
Section 1 - About the Company
  • Allergan Plc - Key Facts
  • Allergan Plc - Key Employees
  • Allergan Plc - Key Employee Biographies
  • Allergan Plc - Major Products and Services
  • Allergan Plc - History
  • Allergan Plc - Company Statement
  • Allergan Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Allergan Plc - Business Description
  • Business Segment: International Brands Segment
  • Overview
  • Performance
  • Business Segment: US General Medicine Segment
  • Overview
  • Performance
  • Business Segment: US Specialized Therapeutics Segment
  • Overview
  • Performance
  • R&D Overview
  • Allergan Plc - Corporate Strategy
  • Allergan Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Allergan Plc - Strengths
  • Allergan Plc - Weaknesses
  • Allergan Plc - Opportunities
  • Allergan Plc - Threats
  • Allergan Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Allergan Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 21, 2018: New report shines light on disconnect between patient and physicians when it comes to the seriousness of IBS, leading to slow diagnosis
  • Feb 16, 2018: Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
  • Feb 06, 2018: Allergan Reports Total Net Revenue Of $4.33 Billion In The Fourth Quarter Of 2017
  • Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference
  • Jan 04, 2018: Allergan to cut over 1,000 jobs to reduce costs
  • Dec 18, 2017: Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations
  • Nov 08, 2017: Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans
  • Nov 01, 2017: Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion
  • Oct 11, 2017: Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference
  • Oct 05, 2017: Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Allergan Plc, Key Facts
  • Allergan Plc, Key Employees
  • Allergan Plc, Key Employee Biographies
  • Allergan Plc, Major Products and Services
  • Allergan Plc, History
  • Allergan Plc, Other Locations
  • Allergan Plc, Subsidiaries
  • Allergan Plc, Key Competitors
  • Allergan Plc, Ratios based on current share price
  • Allergan Plc, Annual Ratios
  • Allergan Plc, Annual Ratios
  • Allergan Plc, Annual Ratios
  • Allergan Plc, Interim Ratios
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Allergan Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Allergan Plc, Performance Chart (2013 - 2017)
  • Allergan Plc, Ratio Charts
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Gilead Sciences Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Amgen Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll